Group | ALV/placebo Dosage | BLP/placebo Dosage | Action Phase |
---|---|---|---|
Cell Control (CC) | DMEM | N | N |
ALV Control (AC) | 5 × 104 TCID50 | N | N |
ALV + BL21 supernatant (AS) | 5 × 104 TCID50 | purified BL21 culture | 2 h after ALV infection |
ALV + BLP (AB) | 5 × 104 TCID50 | 50 μg purified BLP | 2 h after ALV infection |
BLP + ALV (BA) | 5 × 104 TCID50 | 50 μg purified BLP | 2 h before ALV infection |
ALV and BLP together (A&B) | 5 × 104 TCID50 | 50 μg purified BLP | Together with ALV infection |